Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

References

• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 WHO classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20. doi:10.1007/s00401-016-1545-1. PMID:27157931).
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15(Suppl 2):ii1–56. doi:10.1093/neuonc/not151. PMID:24137015.
   PubMed Web of Science ®Google Scholar
• Weller M, ven den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lacet Oncol. 2017;18(6):e315–e29.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse infiltrating oligodendroglioma and astrocytoma. J Clin Oncol. 2017;35(21):2394–401. doi:10.1200/JCO.2017.72.6737. PMID:28640702.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40. doi:10.1200/JCO.2008.19.8721. PMID:19720927.
   PubMed Web of Science ®Google Scholar
• Moller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012;51(6):797–804. doi:10.3109/0284186X.2012.681063. PMID:22548369.
   PubMed Web of Science ®Google Scholar
• Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173–80. doi:10.3171/2008.4.17492. PMID:18834263.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14(21):7068–73. doi:10.1158/1078-0432.CCR-08-0260. PMID:18981004.
   PubMed Web of Science ®Google Scholar
• Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD. Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival. J Neurooncol. 2013;115(2):267–76.doi:10.1007/s11060-013-1225-0. PMID:23974656.
   PubMed Web of Science ®Google Scholar
• Gil MJ, de Las Penas R, Reynes G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs. 2012;23(6):659–65. doi:10.1097/CAD.0b013e3283534d3e. PMID:22634799.
   PubMed Web of Science ®Google Scholar
• Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol. 2011;50(5):630–5. doi:10.3109/0284186X.2011.572913. PMID:21495907.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48(1):52–8. doi:10.1080/02841860802537924. PMID:19031176.
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779–87 doi:10.1212/ 01.wnl.0000304121.57857.38. PMID:18316689.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011;13(10):1143–50. doi:10.1093/neuonc/nor091. PMID:21865400.
   PubMed Web of Science ®Google Scholar
• Seystahl K, Wiestler B, Hundsberger T, Happold C, Wick W, Weller M, Wick A. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas. Eur Neurol. 2013;69(2):95–101. doi:10.1159/000343811. PMID:23182901
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol. 2009;91(3):359–67. doi:10.1007/s11060-008-9722-2. PMID:18953491.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer. 2009;115(8):1734–43. doi:10.1002/cncr.24179. PMID:19197992.
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8(2):189–93. doi:10.1215/15228517-2005-010. PMID:16533878.
   PubMed Web of Science ®Google Scholar
• Weller M, Stupp R, Hegi ME, van den Bent M, Tonn JC, Sanson M, Wick W, Reifenberger G. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol. 2012;14(Suppl 4):iv100–8. doi:10.1093/neuonc/nos206. PMID:23095825.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–90. doi:10.1200/JCO.2013.49.3726. PMID:24516018.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Otmar D, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. doi:10.1007/s00401-007-0243-4. PMID:17618441.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–72. doi:10.1200/JCO.2009.26.3541. PMID:20231676.
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87. doi:10.1002/(SICI)1097-0258(19960229)15:4%3c361::AID-SIM168%3e3.0.CO;2-4. PMID:8668867.
   PubMed Web of Science ®Google Scholar
• Poulsen HS, Urup T, Michaelsen SR, Staberg M, Villingshøj M, Lassen U. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients. Cancer Manag Res. 2014;6:373–87. doi:10.2147/CMAR.S39306. PMID:25298738.
   PubMed Web of Science ®Google Scholar
• Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L, Pujol T, Acebes JJ, Ribalta T, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer. 2003;97(4):1063–71.doi:10.1002/ cncr.11120. PMID:12569607.
   PubMed Web of Science ®Google Scholar
• Gorlia T, Delattre JY, Brandes AA, Kros JM, Taphoorn MJ, Kouwenhoven MC, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, et al. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer. 2013;49(16):3477–85. doi:10.1016/j.ejca.2013.06.039. PMID:23896377.
   PubMed Web of Science ®Google Scholar
• Duerinck J, Clement PM, Bouttens F, Andre C, Neyns B, Staelens Y, Van Fraeyenhove F, Baurain JF, Luce S, D'hondt L, et al. Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma. J Neurol. 2015;262(3):742–51. doi:10.1007/s00415-014-7633-z. PMID:25572162.
   PubMed Web of Science ®Google Scholar
• Nuno M, Birch K, Mukherjee D, Sarmiento JM, Black KL, Patil CG. Survival and prognostic factors of anaplastic gliomas. Neurosurgery. 2013;73(3):458–65.doi:10.1227/01.neu.0000431477.02408.5e. PMID:23719055.
   PubMed Web of Science ®Google Scholar
• Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4):551–9. doi:10.1007/s00401-014-1326-7. PMID:25143301.
   PubMed Web of Science ®Google Scholar
• Levidou G, El-Habr E, Saetta AA, Bamias C, Katsouyanni K, Patsouris E, Korkolopoulou P. P53 immunoexpression as a prognostic marker for human astrocytomas: a meta-analysis and review of the literature. J Neurooncol. 2010;100(3):363–71. doi:10.1007/s11060-010-0204-y. PMID:20461443.
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. The future of high-grade glioma: where we are and where are we going. Surg Neurol Int. 2015;6(Suppl 1):S9–S44. PMID:25722939.
   PubMedGoogle Scholar
• Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15. doi:10.1016/S1470-2045(12)70164-X. PMID:22578793.
   PubMed Web of Science ®Google Scholar
• Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18:1529–37. PMID:27370396.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390(10103):1645–1653. doi: 10.1016/S0140-6736(17)31442-3.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337–43. doi:10.1200/JCO.2012.43.2674. PMID:23071247.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344–50. doi:10.1200/JCO.2012.43.2229. PMID:23071237.
   PubMed Web of Science ®Google Scholar
• Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P, Gu A. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One. 2013;8(7):e68782. doi:10.1371/journal.pone.0068782. PMID:23894344.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32:783–90. doi:10.1200/JCO.2013.49.3726. PMID:24516018.
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150–4. doi:10.1200/JCO.2009.21.9832. PMID:19636000.
   PubMed Web of Science ®Google Scholar
• Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Crinière E, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology. 2010;74:1886–90. doi:10.1212/WNL.0b013e3181e1cf3a. PMID:20427748.
   PubMed Web of Science ®Google Scholar
• Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126(3):443–51. doi:10.1007/s00401-013-1156-z. PMID:23904111.
   PubMed Web of Science ®Google Scholar